RA
LKFT

Rise Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Rise Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-425
Closed -$11.7K – 1523
2024
Q4 		$11.7K Hold
425
– – 0.01% 941
2024
Q3 		$12.2K Hold
425
– – 0.01% 953
2024
Q2 		$10.5K Hold
425
– – 0.01% 996
2024
Q1 		$13.7K Buy
+425
New +$15.8K 0.01% 908

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Rise Advisors's LKFT Position: Q1 2025 in Review

Rise Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2025, closing a stake of 425 shares — an estimated $11.7K sold.

Rise Advisors first reported a position in LKFT in Q1 2024 and held it in 4 quarters. The position peaked at $13.7K in Q1 2024. 83 funds tracked by Wall St. Rank hold LKFT as of Q1 2025.

  • Rise Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2025 after selling out during the quarter.
  • Rise Advisors sold 425 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2025, an estimated $11.7K.
  • Rise Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2024 and held it in 4 quarters.
  • Rise Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $13.7K in Q1 2024.
  • 83 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2025.

Based on Rise Advisors's 13F filing for Q1 2025, filed 15 May 2025.